https://orcid.org/0000-0001-8978-8604
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Objective
There is a growing need for biomarkers to predict therapeutic outcome in Crohn’s disease (CD).
Main outcome measures
The aim was to evaluate whether NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio), ELR (eosinophil-to-lymphocyte ratio), and ENLR (eosinophil*neutrophil-to-lymphocyte ratio), could be prognostic biomarkers of endoscopic response (ER) when starting biologics.
Research design and methods
Patients with CD who started biologics were enrolled. Multivariate analysis was used to evaluate whether NLR, PLR, ELR and ENLR at baseline and at w12 could predict ER (Simple Endoscopic Score for Crohn’s disease [SES-CD] ≤2 or SES-CD≤2 and Rutgeerts i0-i1) after 52 weeks of treatment. Area under the curve (AUC) was calculated to find the cutoffs.
Results
107 patients were included. Patients who achieved ER had significantly lower baseline NLR (p = 0.025), ELR (p = 0.013), and ENLR (p = 0.020) compared with those without ER; results after 12 weeks of treatment for ELR (p = 0.006) and ENLR (p = 0.003). AUC was 0.64 (p = 0.003), 0.67 (p = 0.006) and 0.65 (p = 0.014) for NLR, ELR and ENLR.
Conclusions
Low NLR, ELR and ENLR can predict ER and could be used in clinical practice for a better management of CD patients.
Author’s contribution
FC, MG, FSM and AO were responsible for study concept and design and drafted the manuscript. MM was responsible for statistical analysis. FSM and AO were responsible for study supervision. All authors were responsible for acquisition of data and for critical revision of the manuscript for important intellectual content. All authors had access to the study results and reviewed and approved the final manuscript. AO accepts responsibility for the integrity of this work as a whole.
Declaration of interest
Sara Renna served as an advisory board member for AbbVie, Janssen and MSD Pharmaceuticals, and received lecture grants from AbbVie, Janssen, MSD and Takeda Pharmaceuticals. Filippo Mocciaro served as an advisory board member for AbbVie and MSD Pharmaceuticals, and received lecture grants from AbbVie, Janssen, Pfizer and Takeda Pharmaceuticals. Fabio Salvatore Macaluso served as an advisory board member and/or received lecture grants from AbbVie, Biogen, Janssen, MSD, Pfizer, Samsung Bioepis, and Takeda Pharmaceuticals. Ambrogio Orlando served as an advisory board member for AbbVie, MSD, Janssen, Pfizer, Takeda Pharmaceuticals, and received lecture grants from AbbVie, MSD, Sofar, Chiesi, Janssen, Pfizer, and Takeda Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Table of abbreviations
Reviewer disclosures
Peer reviewers in this manuscript have no relevant financial relationships or otherwise to disclose.
Previous presentations
The abstract was awarded with ‘Poster of distinction’ at Crohn’s & Colitis Congress by the American Gastroenterology Association, which took place on January 21st-24th 2021.
Supplementary material
Supplemental data for this article can be accessed here.